This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Psychemedics Corporation Marks 25th Anniversary Milestone

Stocks in this article: PMD

ACTON, Mass., March 12, 2012 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) announced that this year marks the 25 year anniversary celebration of the corporation, the world's leading drug testing company using hair for the detection of drugs of abuse.  Psychemedics, which started commercial operations in 1987, pioneered the use of hair testing for drugs of abuse and has grown to become the global leader in the industry.

(Logo: )

Psychemedics made history by developing the first commercially feasible hair test for drugs of abuse, and has been successfully serving clients for twenty-five years.  After ten years of prior research on thousands of subjects proved that drugs deposited in the hair can be measured, Psychemedics developed patents and a proprietary method of getting the drugs out of the hair. Psychemedics' proprietary technology is now trusted by Fortune 500 companies, major police forces, schools, parents, and organizations all over the world.

Earlier this year the company announced that it received its seventh patent dedicated to liquefying hair to release drug analytes. Like the first patent, this new patent is fundamental to all hair analysis drug testing and helps set Psychemedics apart from all other hair testing technologies.  It is the only hair testing lab to continue to invest in patentable technologies to improve the science of hair testing and is dedicated to improving the drug testing industry.  The corporation continues to expand its international presence and now receives drug samples from six continents.

Psychemedics' record of innovation includes being the:

  • 1st lab to develop and patent the most effective process for liquification of hair to release drugs of abuse
  • 1st lab to develop a system of wash procedures to remove and account for external contamination
  • 1st lab to utilize tandem mass spectrometry (MS/MS) in workplace testing and to utilize the more accurate GC/MS/MS or LC/MS/MS on positive results for marijuana, cocaine, opiates and methamphetamine
  • 1st lab to test for enantiomers of methamphetamine (D & L isomer) in hair to distinguish illegal drugs from Vicks Inhaler
  • 1st lab to develop testing of Ecstasy (MDMA) in hair
  • 1st lab to obtain FDA clearance of hair assays for drugs of abuse, and the only lab to have clearance on all 5 drug classes (and the subcategories within them), not limited to head hair
  • 1st lab to receive College of American Pathologists (CAP) accreditation for drug testing including hair

Recognizing the extraordinary growth and exceptional commitment Psychemedics has made to the industry, Psychemedics Chairman and CEO Ray Kubacki acknowledged all those who have helped pave the way in making Psychemedics a world class organization.

"The key to our success has been a strong, steady commitment to developing and marketing the highest quality drug testing technology available anywhere in the world.  To our customers, associates, partners, and everyone who has contributed to our success, thank you."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs